This 50th Workshop also gives us the opportunity to reflect on the progress of our field, to honor the contributions of those who built this community, and to chart the path forward for the next generation of herpesvirologists.

Wintermute Biomedical joined the global biotechnology community at BIO 2026, connecting with pharmaceutical companies, investors and industry partners to advance the development and commercialisation of Solexan.

Wintermute Biomedical participated in BIO-Europe 2025, connecting with pharmaceutical, biotechnology and investment leaders to advance international partnering opportunities for Solexan.

Wintermute Biomedical Chief Scientific Officer Dr Alyce Mayfosh presented Phase Ib clinical results for Solexan™ at the EADV Congress 2025, sharing findings from Wintermute’s first-in-patient shingles study with the international dermatology community.

Wintermute Biomedical presented Solexan™ to the global biotechnology community at BIO 2025, showcasing our novel topical antiviral and its potential as a new treatment option for herpes zoster (shingles).